COMMUNIQUÉS West-GlobeNewswire
-
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
29/07/2026 -
Realize Medical Appoints Chris Marrus to Board of Directors
29/07/2026 -
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
29/07/2026 -
Rose Hill Life Sciences Appoints Bryan Smith as Scientific Advisor
29/07/2026 -
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
29/07/2026 -
Walmart Canada, Associates and Customers Raise $7.2 Million to Support Children’s Hospitals Across Canada
29/07/2026 -
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
29/07/2026 -
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
29/07/2026 -
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
29/07/2026 -
Cynet Releases 1H 2026 CyOps ECHO Report: Abused Identities, Gateways, and Trust Take the Place of Exploited Code
29/07/2026 -
Walmart Canada, ses associés et ses clients recueillent 7,2 millions de dollars pour soutenir les hôpitaux pour enfants partout au Canada
29/07/2026 -
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
29/07/2026 -
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
29/07/2026 -
MediWound to Report Second Quarter 2026 Financial Results
29/07/2026 -
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
29/07/2026 -
Hyperion DeFi Schedules First Quarter Earnings Call for Wednesday, August 12 at 5:00 p.m. ET
29/07/2026 -
NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative
29/07/2026 -
PROLLENIUM® Expands PACE with Launch of Eight New Clinical Education Modules
29/07/2026 -
TOMI Environmental Solutions Reaffirms $12 Million Revenue Guidance for Fiscal 2026 and Confirms $35 Million Sales Pipeline with $8.6 Million in Advanced Stages
29/07/2026
Pages